Long-term outcomes after intravitreal dexamethasone treatment in steroid responders
ConclusionsThough dexamethasone does predictably lead to an increase in IOP, this adverse effect was effectively managed with topical treatment. The present study suggests that the intravitreal dexamethasone implant may be considered in patients with DME and a history of steroid-induced ocular hypertension who have exhausted first-line treatments.
Source: Acta Diabetologica - Category: Endocrinology Source Type: research
More News: Dexamethasone | Diabetes | Endocrinology | Eye Implants | Eyes | Hypertension | Pathology | Study